Aditxt Inc. Portfolio Company CEO Recognized for Advancements in Women's Health

Aditxt Inc. (NASDAQ: ADTX) has announced that Saundra Pelletier, CEO of Evofem Biosciences, its pending acquisition target, was honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. This recognition underscores Pelletier's leadership in advancing women's sexual and reproductive health through Evofem's innovative products, including the hormone-free contraceptive PHEXXI(R) and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis.

The award coincides with Say Vagina Month, a campaign initiated by Evofem to foster open and accurate discussions about vaginal health. This initiative reflects the company's commitment to breaking taboos and improving women's health outcomes. Aditxt's planned acquisition of Evofem, expected to be finalized in the second half of 2025, signifies a strategic expansion into the women's health sector, aligning with its mission to accelerate promising health innovations.

Aditxt operates as a social innovation platform, bringing together research institutions, industry partners, and shareholders to address significant societal challenges. The acquisition of Evofem is poised to introduce a dedicated women's health program to Aditxt's portfolio, further diversifying its impact. However, the transaction's completion hinges on several conditions, including shareholder approval and Aditxt's ability to raise approximately $17 million to fulfill its financial obligations. For more details on Aditxt's initiatives and updates, visit https://ibn.fm/ADTX.

This development not only highlights the achievements of a leading female entrepreneur in the healthcare sector but also marks a pivotal moment for Aditxt as it seeks to broaden its influence in addressing critical health disparities. The recognition of Pelletier's work and the impending acquisition underscore the growing importance of innovation and inclusivity in healthcare solutions.